Insights

Field, medical-information and congress insights, prioritised and routed to the owning function with full traceability from source to outcome.

Capture insight

Insights captured

-3

High-priority

Insight → action conversion

93%

Target 60%+33% vs target+2

Median time to review

3days

Target 3days0days vs target-0.2

Unresolved high-priority > 14 d

Duplicate rate

9.8%

Insights per month by priority

Excluding duplicates

Totals: Jan 8 · Feb 8 · Mar 4 · Apr 11 · May 11 · Jun 8 · Jul 8 · Aug 9 · Sep 7

Top categories

Top 10 by count

By source type

74insights

MSL interaction34 (46%)
KOL interaction23 (31%)
Advisory board7 (9%)
Medical-information inquiry1 (1%)
Congress8 (11%)
Payer / HTA interaction1 (1%)

Id	Captured	Product	Topic	Category	Source	Priority	Status	Routed to	Flags	AI	Owner
INS-0047	10 Sept 2026	Vantrexa	Brain-metastasis subgroup data Multiple US academic centres are reluctant to use vantrelimab in patients with asymptomatic brain metastases because VOYAGE-1 excluded untreated CNS disease. Absence of subgroup or real-world data drives default to chemo-immunotherapy.	Evidence gap	MSL interaction ENG-0007	Critical 86	Prioritised	—	—	AI-assisted	JWJames Whitfield
INS-0031	18 Jun 2026	Vantrexa	Sequencing after progression UK network drafting post-progression pathway; will default to docetaxel absent sequencing evidence. Time-sensitive opportunity to inform pathway with available data.	Treatment pathway	MSL interaction ENG-0021	Critical 86	Action in progress	Medical Affairs	—	AI-assisted	RARachel Adeyemi
INS-0011	25 Jan 2026	Nephrada	Patient-reported outcomes Patient-reported outcomes: practice variation observed reported by academic nephrologist (GB).	Patient experience	Advisory board ENG-0130	Critical 84	Action in progress	HEOR	—	—	ABDr. Anna Becker
INS-0051	21 Feb 2026	Lumeva	Switching between CGRP agents Switching between CGRP agents: request for data reported by headache specialist (IT).	Health economics	MSL interaction ENG-0211	Critical 83	Action in progress	HEOR	—	AI-assisted	LOLuis Ortega
INS-0060	13 Sept 2026	Vantrexa	PD-L1 testing turnaround Japanese regional PD-L1 turnaround of 10–14 days leads to chemotherapy initiation before results. Suggests Japanese testing-pathway guide and reflex-testing advocacy.	Diagnosis and screening	MSL interaction ENG-0003	Critical 82	Quality review	—	—	Pending review	MTMei Tanaka
INS-0044	14 Aug 2026	Nephrada	eGFR slope interpretation NICE signals proteinuria alone insufficient; 2-year eGFR slope expected for positive recommendation. Increases urgency of GLOMERULAR-REG.	Access and reimbursement	Payer / HTA interaction ENG-0066	Critical 82	Action in progress	Market Access	—	—	ABDr. Anna Becker
INS-0058	11 Sept 2026	Nephrada	Steroid-sparing strategies Potential safety observation: recurrent infections in OLE patient after 14 months; question on IgG monitoring frequency. Flagged for pharmacovigilance handoff.	Safety and tolerability	MSL interaction ENG-0011	High 77	Routed	Safety	Safety	AI disabled	ABDr. Anna Becker
INS-0012	20 Jun 2026	Nephrada	Treatment burden and fatigue Patient advocacy groups prioritise fatigue and prognostic uncertainty over proteinuria; current endpoints perceived as not patient-relevant. Supports adding a fatigue PRO to the registry protocol.	Patient experience	Advisory board INI-0203	High 77	Outcome recorded	HEOR	—	—	SLDr. Sophie Laurent
INS-0068	28 Jul 2026	Lumeva	Drug interactions Drug interactions: practice variation observed reported by primary care physician (ES).	Adherence and persistence	KOL interaction ENG-0185	High 75	Action in progress	HEOR	—	AI-assisted	LOLuis Ortega
INS-0055	08 Sept 2026	Lumeva	Switching between CGRP agents Recurring MI question (14 in 60 days) on washout when switching from anti-CGRP mAbs; no standard response, driving custom-response workload and SLA pressure.	Medical-information need	Medical-information inquiry MI-2026-0788	High 73	Action created	Medical Information	—	AI-assisted	FAFatima Al-Sayed
INS-0010	11 Aug 2026	Vantrexa	PD-L1 testing turnaround PD-L1 testing turnaround: request for data reported by oncology pharmacist (FR).	Education need	Congress ENG-0112	High 73	Action in progress	Medical Affairs	—	—	MTMei Tanaka
INS-0023	26 May 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: request for data reported by oncology pharmacist (US).	Diagnosis and screening	MSL interaction ENG-0071	High 73	Outcome recorded	Medical Affairs	—	AI-assisted	JWJames Whitfield
INS-0039	22 Jul 2026	Lumeva	Medication-overuse headache Interest in IIS on lumevarin in chronic migraine with medication-overuse headache; population under-represented in trials.	Evidence gap	KOL interaction ENG-0044	High 72	Action in progress	HEOR	—	—	LOLuis Ortega
INS-0019	02 May 2026	Lumeva	Chronic migraine data Chronic migraine data: interest in collaboration reported by headache specialist (BR).	Adherence and persistence	Congress ENG-0209	High 72	Action in progress	HEOR	—	AI-assisted	LOLuis Ortega
INS-0064	30 Apr 2026	Vantrexa	PD-L1 testing turnaround PD-L1 testing turnaround: practice variation observed reported by pathologist (JP).	Evidence gap	MSL interaction ENG-0056	High 71	Action in progress	HEOR	—	AI-assisted	JWJames Whitfield
INS-0061	14 Sept 2026	Vantrexa	Infusion-reaction management Pharmacists improvising premedication after grade 1 infusion reaction; SmPC not explicit. Supports finishing the 4 outstanding infusion-reaction standard responses.	Medical-information need	MSL interaction ENG-0002	High 69	Submitted	—	—	Pending review	RARachel Adeyemi
INS-0056	20 Aug 2026	Lumeva	Dosing in hepatic impairment Dosing in hepatic impairment: request for data reported by general neurologist (DE).	Medical-information need	MSL interaction ENG-0172	High 69	Action created	Medical Information	—	AI-assisted	JWJames Whitfield
INS-0067	07 Jul 2026	Vantrexa	PD-L1 testing turnaround PD-L1 testing turnaround: request for data reported by thoracic medical oncologist (DE).	Education need	MSL interaction ENG-0104	High 69	Action in progress	Medical Affairs	—	—	JWJames Whitfield
INS-0005	24 Aug 2026	Lumeva	Dosing in hepatic impairment Dosing in hepatic impairment: request for data reported by primary care physician (CA).	Health economics	MSL interaction ENG-0187	High 68	Action created	HEOR	—	AI-assisted	LOLuis Ortega
INS-0030	14 Jun 2026	Nephrada	APRIL pathway mechanism APRIL pathway mechanism: practice variation observed reported by academic nephrologist (DE).	Education need	MSL interaction ENG-0135	High 66	Outcome recorded	Medical Affairs	Regulatory	AI-assisted	ABDr. Anna Becker
INS-0081	07 Sept 2026	Nephrada	Treatment burden and fatigue Treatment burden and fatigue: request for data reported by renal pathologist (GB).	Patient experience	Congress ENG-0156	High 65	Prioritised	—	—	—	ABDr. Anna Becker
INS-0021	24 Jun 2026	Lumeva	Chronic migraine data Chronic migraine data: practice variation observed reported by primary care physician (CA).	Medical-information need	MSL interaction ENG-0167	High 63	Outcome recorded	Medical Information	—	AI-assisted	LOLuis Ortega
INS-0066	02 Sept 2026	Vantrexa	Infusion-reaction management Infusion-reaction management: practice variation observed reported by radiation oncologist (JP).	Competitor activity	KOL interaction ENG-0092	Medium 61	Submitted	—	—	AI-assisted	MTMei Tanaka
INS-0028	08 Feb 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: recurring question reported by thoracic medical oncologist (FR).	Competitor activity	KOL interaction ENG-0058	Medium 60	Action in progress	Medical Communications	—	AI-assisted	MTMei Tanaka
INS-0045	18 Aug 2026	Lumeva	Switching between CGRP agents Switching between CGRP agents: recurring question reported by primary care physician (CA).	Health economics	MSL interaction ENG-0221	Medium 59	Prioritised	—	—	AI-assisted	JWJames Whitfield
INS-0043	07 Jul 2026	Nephrada	Steroid-sparing strategies Steroid-sparing strategies: gap in current materials reported by academic nephrologist (GB).	Access and reimbursement	KOL interaction ENG-0138	Medium 59	Outcome recorded	Market Access	—	AI-assisted	ABDr. Anna Becker
INS-0003	11 Aug 2026	Vantrexa	Brain-metastasis subgroup data Brain-metastasis subgroup data: request for data reported by thoracic medical oncologist (GB).	Treatment pathway	KOL interaction ENG-0096	Medium 58	Routed	Medical Affairs	—	AI-assisted	JWJames Whitfield
INS-0008	10 Jul 2026	Lumeva	Switching between CGRP agents Switching between CGRP agents: request for data reported by primary care physician (AU).	Medical-information need	KOL interaction ENG-0204	Medium 57	Outcome recorded	Medical Information	Regulatory	AI-assisted	LOLuis Ortega
INS-0035	22 Jun 2026	Nephrada	eGFR slope interpretation eGFR slope interpretation: request for data reported by renal pathologist (GB).	Evidence gap	MSL interaction ENG-0155	Medium 57	Action in progress	HEOR	—	AI-assisted	ABDr. Anna Becker
INS-0026	10 Aug 2026	Vantrexa	Brain-metastasis subgroup data Brain-metastasis subgroup data: recurring question reported by thoracic medical oncologist (US).	Competitor activity	MSL interaction ENG-0090	Medium 56	Action created	Medical Communications	—	AI-assisted	RARachel Adeyemi
INS-0062	19 Apr 2026	Lumeva	Drug interactions Drug interactions: practice variation observed reported by headache specialist (ES).	Evidence gap	KOL interaction ENG-0177	Medium 53	Action in progress	HEOR	—	AI-assisted	LOLuis Ortega
INS-0013	02 Jul 2026	Lumeva	Chronic migraine data Chronic migraine data: practice variation observed reported by primary care physician (AU).	Evidence gap	Congress ENG-0188	Medium 52	Action in progress	HEOR	—	AI-assisted	LOLuis Ortega
INS-0020	05 Jun 2026	Vantrexa	Infusion-reaction management Infusion-reaction management: interest in collaboration reported by thoracic medical oncologist (IT).	Diagnosis and screening	MSL interaction ENG-0086	Medium 52	Outcome recorded	Medical Affairs	—	—	MTMei Tanaka
INS-0076	12 Aug 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: request for data reported by radiation oncologist (US).	Treatment pathway	KOL interaction ENG-0068	Medium 48	Action in progress	Medical Affairs	—	AI-assisted	JWJames Whitfield
INS-0004	28 Jan 2026	Vantrexa	Brain-metastasis subgroup data Brain-metastasis subgroup data: request for data reported by thoracic medical oncologist (JP).	Efficacy	MSL interaction ENG-0028	Low 40	Action in progress	Clinical Development	—	—	RARachel Adeyemi
INS-0069	23 Jul 2026	Lumeva	Chronic migraine data Chronic migraine data: request for data reported by general neurologist (ES).	Medical-information need	KOL interaction ENG-0165	Low 37	Outcome recorded	Medical Information	—	AI-assisted	LOLuis Ortega
INS-0074	01 Aug 2026	Nephrada	eGFR slope interpretation eGFR slope interpretation: interest in collaboration reported by academic nephrologist (GB).	Unmet medical need	KOL interaction ENG-0124	Critical 79	Closed	Clinical Development	—	AI-assisted	ABDr. Anna Becker
INS-0022	02 Jun 2026	Vantrexa	Comparator checkpoint monotherapy Competitor TIGIT failure raising class scepticism; KOLs request clear mechanistic differentiation. Recommend scientific platform update and reactive slide.	Competitor activity	Congress CON-0001	Critical 78	Closed	Medical Communications	—	—	JWJames Whitfield
INS-0053	08 Jan 2026	Vantrexa	Brain-metastasis subgroup data Brain-metastasis subgroup data: gap in current materials reported by oncology pharmacist (ES).	Efficacy	MSL interaction ENG-0054	High 76	Archived	Clinical Development	—	AI-assisted	RARachel Adeyemi
INS-0025	03 Feb 2026	Nephrada	Treatment burden and fatigue Treatment burden and fatigue: gap in current materials reported by community nephrologist (GB).	Evidence gap	Advisory board ENG-0150	High 73	Closed	HEOR	—	AI-assisted	ABDr. Anna Becker
INS-0080	24 Mar 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: request for data reported by oncology pharmacist (JP).	Evidence gap	KOL interaction ENG-0069	High 71	Deduplicated	HEOR	—	—	MTMei Tanaka
INS-0001	01 Jun 2026	Lumeva	Drug interactions Drug interactions: interest in collaboration reported by primary care physician (ES).	Clinical practice	MSL interaction ENG-0205	High 70	Closed	Medical Affairs	—	AI-assisted	LOLuis Ortega
INS-0070	17 Jan 2026	Vantrexa	Sequencing after progression Sequencing after progression: gap in current materials reported by pathologist (DE).	Competitor activity	MSL interaction ENG-0047	High 69	Closed	Medical Communications	—	AI-assisted	JWJames Whitfield
INS-0015	17 May 2026	Lumeva	Real-world persistence Real-world persistence: gap in current materials reported by headache specialist (BR).	Treatment pathway	KOL interaction ENG-0198	High 68	Archived	Medical Affairs	—	AI-assisted	JWJames Whitfield
INS-0049	15 Apr 2026	Nephrada	Patient-reported outcomes Patient-reported outcomes: request for data reported by renal pathologist (US).	Unmet medical need	KOL interaction ENG-0142	High 68	Closed	Clinical Development	—	AI-assisted	ABDr. Anna Becker
INS-0029	14 Apr 2026	Vantrexa	Elderly / ECOG 2 patients Elderly / ECOG 2 patients: gap in current materials reported by thoracic medical oncologist (DE).	Education need	KOL interaction ENG-0008	High 66	Closed	Medical Affairs	—	AI-assisted	JWJames Whitfield
INS-0034	14 Feb 2026	Lumeva	Dosing in hepatic impairment Dosing in hepatic impairment: request for data reported by headache specialist (BR).	Clinical practice	Advisory board ENG-0203	High 65	Deduplicated	Medical Affairs	—	—	LOLuis Ortega
INS-0009	01 May 2026	Vantrexa	Elderly / ECOG 2 patients Elderly / ECOG 2 patients: interest in collaboration reported by oncology pharmacist (ES).	Product understanding	MSL interaction ENG-0036	High 64	Closed	Medical Communications	—	AI-assisted	RARachel Adeyemi
INS-0002	03 Feb 2026	Lumeva	Drug interactions Drug interactions: recurring question reported by primary care physician (AU).	Health economics	KOL interaction ENG-0208	High 63	Closed	HEOR	—	AI-assisted	LOLuis Ortega
INS-0041	27 Jan 2026	Aurelin	Adolescent population Adolescent population: recurring question reported by dermatologist (GB).	Product understanding	KOL interaction ENG-0229	High 63	Closed	Medical Communications	—	AI-assisted	RARachel Adeyemi
INS-0075	16 Jan 2026	Vantrexa	Comparator checkpoint monotherapy Comparator checkpoint monotherapy: gap in current materials reported by thoracic medical oncologist (IT).	Efficacy	MSL interaction ENG-0049	High 63	Closed	Clinical Development	—	AI-assisted	RARachel Adeyemi
INS-0017	25 Jun 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: practice variation observed reported by oncology pharmacist (ES).	Evidence gap	Congress ENG-0017	High 62	Deduplicated	HEOR	Regulatory	AI-assisted	RARachel Adeyemi
INS-0048	23 Apr 2026	Vantrexa	Duration of response Duration of response: gap in current materials reported by pathologist (FR).	Treatment pathway	KOL interaction ENG-0098	Medium 61	Closed	Medical Affairs	—	—	JWJames Whitfield
INS-0018	18 May 2026	Lumeva	Chronic migraine data Chronic migraine data: gap in current materials reported by primary care physician (ES).	Evidence gap	Advisory board ENG-0223	Medium 60	Archived	HEOR	—	AI-assisted	LOLuis Ortega
INS-0065	10 May 2026	Vantrexa	Brain-metastasis subgroup data Brain-metastasis subgroup data: interest in collaboration reported by radiation oncologist (DE).	Efficacy	MSL interaction ENG-0077	Medium 60	Deduplicated	Clinical Development	—	AI-assisted	RARachel Adeyemi
INS-0077	11 May 2026	Lumeva	Switching between CGRP agents Switching between CGRP agents: recurring question reported by primary care physician (IT).	Adherence and persistence	MSL interaction ENG-0191	Medium 59	Closed	HEOR	—	AI-assisted	LOLuis Ortega
INS-0072	10 May 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: interest in collaboration reported by thoracic medical oncologist (US).	Evidence gap	Advisory board ENG-0020	Medium 59	Closed	HEOR	—	—	JWJames Whitfield
INS-0057	02 Mar 2026	Lumeva	Switching between CGRP agents Switching between CGRP agents: request for data reported by headache specialist (BR).	Adherence and persistence	KOL interaction ENG-0225	Medium 59	Archived	HEOR	—	AI-assisted	LOLuis Ortega
INS-0032	07 Feb 2026	Vantrexa	Elderly / ECOG 2 patients Elderly / ECOG 2 patients: gap in current materials reported by thoracic medical oncologist (FR).	Product understanding	MSL interaction ENG-0087	Medium 59	Closed	Medical Communications	—	—	RARachel Adeyemi
INS-0054	24 Jan 2026	Lumeva	Real-world persistence Real-world persistence: request for data reported by headache specialist (US).	Health economics	Congress ENG-0175	Medium 58	Deduplicated	HEOR	—	AI-assisted	LOLuis Ortega
INS-0078	19 Jan 2026	Aurelin	Phase IIb efficacy Phase IIb efficacy: request for data reported by allergist (DE).	Product understanding	Advisory board ENG-0231	Medium 58	Closed	Medical Communications	—	AI-assisted	RARachel Adeyemi
INS-0073	03 May 2026	Vantrexa	Sequencing after progression Sequencing after progression: request for data reported by thoracic medical oncologist (US).	Competitor activity	MSL interaction ENG-0046	Medium 57	Closed	Medical Communications	—	AI-assisted	RARachel Adeyemi
INS-0027	07 Jan 2026	Nephrada	Proteinuria as surrogate endpoint Proteinuria as surrogate endpoint: interest in collaboration reported by renal pathologist (US).	Patient experience	Congress ENG-0125	Medium 57	Closed	HEOR	—	AI-assisted	ABDr. Anna Becker
INS-0014	08 May 2026	Vantrexa	Duration of response Duration of response: recurring question reported by thoracic medical oncologist (US).	Product understanding	KOL interaction ENG-0041	Medium 56	Closed	Medical Communications	—	AI-assisted	JWJames Whitfield
INS-0024	23 Mar 2026	Vantrexa	PD-L1 testing turnaround PD-L1 testing turnaround: gap in current materials reported by radiation oncologist (FR).	Competitor activity	Congress ENG-0062	Medium 56	Deduplicated	Medical Communications	—	AI-assisted	RARachel Adeyemi
INS-0033	09 May 2026	Vantrexa	Elderly / ECOG 2 patients Elderly / ECOG 2 patients: practice variation observed reported by thoracic medical oncologist (FR).	Competitor activity	MSL interaction ENG-0103	Medium 55	Closed	Medical Communications	—	AI-assisted	RARachel Adeyemi
INS-0037	18 Apr 2026	Lumeva	Drug interactions Drug interactions: practice variation observed reported by headache specialist (JP).	Adherence and persistence	KOL interaction ENG-0212	Medium 55	Closed	HEOR	—	AI-assisted	LOLuis Ortega
INS-0082	01 Apr 2026	Vantrexa	Elderly / ECOG 2 patients Elderly / ECOG 2 patients: practice variation observed reported by oncology pharmacist (DE).	Evidence gap	MSL interaction ENG-0088	Medium 55	Closed	HEOR	—	AI-assisted	JWJames Whitfield
INS-0038	19 Mar 2026	Vantrexa	PD-L1 testing turnaround PD-L1 testing turnaround: request for data reported by pathologist (FR).	Efficacy	Congress ENG-0006	Medium 55	Archived	Clinical Development	—	AI-assisted	RARachel Adeyemi
INS-0042	01 Feb 2026	Nephrada	Steroid-sparing strategies Steroid-sparing strategies: interest in collaboration reported by renal pathologist (FR).	Evidence gap	MSL interaction ENG-0151	Medium 55	Closed	HEOR	—	AI-assisted	ABDr. Anna Becker
INS-0071	28 Feb 2026	Nephrada	Steroid-sparing strategies Steroid-sparing strategies: request for data reported by community nephrologist (US).	Patient experience	MSL interaction ENG-0143	Medium 54	Closed	HEOR	—	AI-assisted	ABDr. Anna Becker
INS-0063	23 Jan 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: interest in collaboration reported by oncology pharmacist (IT).	Clinical practice	Congress ENG-0025	Medium 54	Deduplicated	Medical Affairs	—	AI-assisted	RARachel Adeyemi
INS-0016	14 Apr 2026	Nephrada	Treatment burden and fatigue Treatment burden and fatigue: interest in collaboration reported by community nephrologist (DE).	Access and reimbursement	KOL interaction ENG-0126	Medium 53	Closed	Market Access	—	AI-assisted	ABDr. Anna Becker
INS-0046	03 Feb 2026	Vantrexa	PD-L1 testing turnaround PD-L1 testing turnaround: practice variation observed reported by thoracic medical oncologist (US).	Treatment pathway	MSL interaction ENG-0085	Medium 53	Archived	Medical Affairs	—	AI-assisted	RARachel Adeyemi
INS-0006	18 Jan 2026	Vantrexa	PD-L1 testing turnaround PD-L1 testing turnaround: request for data reported by thoracic medical oncologist (DE).	Evidence gap	KOL interaction ENG-0010	Medium 53	Deduplicated	HEOR	—	AI-assisted	JWJames Whitfield
INS-0050	05 Jul 2026	Lumeva	Real-world persistence Real-world persistence: gap in current materials reported by headache specialist (US).	Evidence gap	MSL interaction ENG-0190	Medium 52	Closed	HEOR	—	AI-assisted	LOLuis Ortega
INS-0036	27 Apr 2026	Lumeva	Medication-overuse headache Medication-overuse headache: request for data reported by headache specialist (DE).	Health economics	MSL interaction ENG-0206	Medium 50	Archived	HEOR	—	AI-assisted	JWJames Whitfield
INS-0079	11 Apr 2026	Vantrexa	Duration of response Duration of response: interest in collaboration reported by oncology pharmacist (JP).	Diagnosis and screening	MSL interaction ENG-0105	Medium 49	Closed	Medical Affairs	—	AI-assisted	RARachel Adeyemi
INS-0052	02 Mar 2026	Vantrexa	Infusion-reaction management Infusion-reaction management: practice variation observed reported by headache specialist (ES).	Product understanding	KOL interaction ENG-0032	Medium 49	Closed	Medical Communications	—	AI-assisted	JWJames Whitfield
INS-0040	31 Mar 2026	Vantrexa	Chemotherapy-free first line Chemotherapy-free first line: interest in collaboration reported by radiation oncologist (FR).	Efficacy	Congress ENG-0051	Medium 45	Closed	Clinical Development	—	AI-assisted	JWJames Whitfield
INS-0059	10 May 2026	Nephrada	Treatment burden and fatigue Treatment burden and fatigue: recurring question reported by renal pathologist (GB).	Education need	Advisory board ENG-0146	Low 43	Closed	Medical Affairs	—	AI-assisted	ABDr. Anna Becker
INS-0007	17 Apr 2026	Nephrada	Patient-reported outcomes Patient-reported outcomes: practice variation observed reported by community nephrologist (GB).	Education need	KOL interaction ENG-0160	Low 35	Closed	Medical Affairs	—	AI-assisted	ABDr. Anna Becker

82 of 82 insights · open insights first, then by priority score

Themes (22)

Insights grouped by topic, excluding duplicates. Emerging = ≥ 60% of occurrences in the last 60 days. Recurring = seen in ≥ 3 different months.

Topic	Insights	Mean score	Products	Countries	Routed	Closed	First seen	Last seen	Pattern
PD-L1 testing turnaround	6	67	Vantrexa	JP, FR, DE, US	83%	33%	03 Feb 2026	13 Sept 2026	Recurring
Switching between CGRP agents	6	65	Lumeva	ES, CA, AU, IT, BR	83%	33%	21 Feb 2026	08 Sept 2026	Recurring
Brain-metastasis subgroup data	5	63	Vantrexa	US, GB, JP, ES	80%	20%	08 Jan 2026	10 Sept 2026	EmergingRecurring
Drug interactions	5	63	Lumeva	ES, JP, AU	100%	60%	03 Feb 2026	28 Jul 2026	Recurring
Treatment burden and fatigue	5	62	Nephrada	GB, DE	80%	60%	03 Feb 2026	07 Sept 2026	Recurring
Elderly / ECOG 2 patients	5	60	Vantrexa	FR, ES, DE	100%	100%	07 Feb 2026	09 May 2026	Recurring
Chemotherapy-free first line	5	57	Vantrexa	US, FR	100%	40%	08 Feb 2026	12 Aug 2026	Recurring
Chronic migraine data	5	57	Lumeva	ES, AU, CA, BR	100%	20%	02 May 2026	23 Jul 2026	Recurring
Steroid-sparing strategies	4	61	Nephrada	DE, GB, US, FR	100%	50%	01 Feb 2026	11 Sept 2026	Recurring
Infusion-reaction management	4	58	Vantrexa	GB, JP, IT, ES	50%	25%	02 Mar 2026	14 Sept 2026	Recurring
eGFR slope interpretation	3	73	Nephrada	GB	100%	33%	22 Jun 2026	14 Aug 2026	Emerging
Sequencing after progression	3	71	Vantrexa	GB, US, DE	100%	67%	17 Jan 2026	18 Jun 2026	Recurring
Patient-reported outcomes	3	62	Nephrada	GB, US	100%	67%	25 Jan 2026	17 Apr 2026	—
Duration of response	3	55	Vantrexa	US, FR, JP	100%	100%	11 Apr 2026	08 May 2026	—
Comparator checkpoint monotherapy	2	71	Vantrexa	US, IT	100%	100%	16 Jan 2026	02 Jun 2026	—
Dosing in hepatic impairment	2	69	Lumeva	CA, DE	100%	0%	20 Aug 2026	24 Aug 2026	Emerging
Medication-overuse headache	2	61	Lumeva	ES, DE	100%	50%	27 Apr 2026	22 Jul 2026	—
Real-world persistence	2	60	Lumeva	US, BR	100%	100%	17 May 2026	05 Jul 2026	—
APRIL pathway mechanism	1	66	Nephrada	DE	100%	0%	14 Jun 2026	14 Jun 2026	—
Adolescent population	1	63	Aurelin	GB	100%	100%	27 Jan 2026	27 Jan 2026	—
Phase IIb efficacy	1	58	Aurelin	DE	100%	100%	19 Jan 2026	19 Jan 2026	—
Proteinuria as surrogate endpoint	1	57	Nephrada	US	100%	100%	07 Jan 2026	07 Jan 2026	—

Unresolved evidence gaps (6)

Evidence-gap insights grouped by gap category, with whether an evidence project exists for the gap

Evidence gap	Insights	Open	Products	Evidence project
Chronic migraine data	2	1	Lumeva	No project
Outcomes in brain-metastasis subgroup	1	1	Vantrexa	EVP-0002Scientific review
Outcomes in patients with medication-overuse headache	1	1	Lumeva	EVP-0008Feasibility review
eGFR slope interpretation	1	1	Nephrada	No project
PD-L1 testing turnaround	1	1	Vantrexa	No project
Drug interactions	1	1	Lumeva	No project
Real-world persistence	1	0	Lumeva	No project
Chemotherapy-free first line	1	0	Vantrexa	No project
Elderly / ECOG 2 patients	1	0	Vantrexa	No project
Treatment burden and fatigue	1	0	Nephrada	No project
Steroid-sparing strategies	1	0	Nephrada	No project

Id	Title	Insight	Owner function	Owner	Due	Status	Result	Outcome
ACT-0008	Evaluate fatigue PRO instrument for GLOMERULAR-REG protocol	INS-0012	HEOR	NPDr. Nikolai Petrov	15 Aug 2026	Completed	Decision · DEC-0004	FACIT-Fatigue added to registry protocol v0.4; decision DEC-0004 approved.

1 of 7 actions

Workflow funnel

Current count of insights at each stage (PRD §12 order)

Captured
0
Draft
0
Submitted
2
Quality review
1
Categorised
0
Deduplicated
8
Prioritised
3
Routed
2
Action created
4
Action in progress
16
Outcome recorded
8
Closed
31
Archived
7

Median capture → review

3 days

n = 80

Median review → close

40.5 days

n = 44

Median capture → close

43 days

n = 44

Routing timestamps are not held in the sample data, so capture → route is not shown.

Prioritisation model

Weighted score, maximum 100

Dimension	Weight
Patient relevance	20%
Strategic alignment	20%
Scientific importance	15%
Urgency	15%
Novelty	10%
Actionability	10%
Confidence	5%
Breadth of occurrence	5%

Priority bands: Critical ≥ 78, High ≥ 62, Medium ≥ 45, Low below.

Scores are explainable and editable by authorised users; every edit is audited.